Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Zumsteg

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current Opinion in Oncology|January 7, 2009
Corrupt policemen: inflammatory cells promote tumor angiogenesisAdrian Zumsteg, Gerhard Christofori
Cold Spring Harbor Perspectives in Medicine|June 8, 2012
Myeloid cells and lymphangiogenesisAdrian Zumsteg, Gerhard Christofori
The Journal of Biological Chemistry|July 26, 2003
Nuclear receptors constitutive androstane receptor and pregnane X receptor activate a drug-responsive enhancer of the murine 5-aminolevulinic acid synthase geneDavid J Fraser, Adrian Zumsteg, Urs A Meyer
Carcinogenesis|June 10, 2010
A bioluminescent mouse model of pancreatic {beta}-cell carcinogenesisAdrian Zumsteg, Karin Strittmatter, Daniela Klewe-Nebenius, et al.
Plos One|September 18, 2009
Myeloid cells contribute to tumor lymphangiogenesisAdrian Zumsteg, Vanessa Baeriswyl, Natsuko Imaizumi, et al.
Molecular Cancer Research : MCR|May 8, 2012
Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinomaAdrian Zumsteg, Christoph Caviezel, Laura Pisarsky, et al.
Elife|April 10, 2014
In vivo reprogramming of pancreatic acinar cells to three islet endocrine subtypesWeida Li, Mio Nakanishi, Adrian Zumsteg, et al.
Molecular Cancer Therapeutics|January 14, 2009
Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesisTibor Schomber, Adrian Zumsteg, Karin Strittmatter, et al.
Current Pathobiology Reports|March 22, 2016
Direct Reprogramming for Pancreatic Beta-Cells Using Key Developmental GenesClaudia Cavelti-Weder, Weida Li, Adrian Zumsteg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2015
Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse ModelRuben Bill, Ernesta Fagiani, Adrian Zumsteg, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Opinion in Oncology|January 7, 2009
Corrupt policemen: inflammatory cells promote tumor angiogenesisAdrian Zumsteg, Gerhard Christofori
Cold Spring Harbor Perspectives in Medicine|June 8, 2012
Myeloid cells and lymphangiogenesisAdrian Zumsteg, Gerhard Christofori
The Journal of Biological Chemistry|July 26, 2003
Nuclear receptors constitutive androstane receptor and pregnane X receptor activate a drug-responsive enhancer of the murine 5-aminolevulinic acid synthase geneDavid J Fraser, Adrian Zumsteg, Urs A Meyer
Carcinogenesis|June 10, 2010
A bioluminescent mouse model of pancreatic {beta}-cell carcinogenesisAdrian Zumsteg, Karin Strittmatter, Daniela Klewe-Nebenius, et al.
Plos One|September 18, 2009
Myeloid cells contribute to tumor lymphangiogenesisAdrian Zumsteg, Vanessa Baeriswyl, Natsuko Imaizumi, et al.
Molecular Cancer Research : MCR|May 8, 2012
Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinomaAdrian Zumsteg, Christoph Caviezel, Laura Pisarsky, et al.
Elife|April 10, 2014
In vivo reprogramming of pancreatic acinar cells to three islet endocrine subtypesWeida Li, Mio Nakanishi, Adrian Zumsteg, et al.
Molecular Cancer Therapeutics|January 14, 2009
Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesisTibor Schomber, Adrian Zumsteg, Karin Strittmatter, et al.
Current Pathobiology Reports|March 22, 2016
Direct Reprogramming for Pancreatic Beta-Cells Using Key Developmental GenesClaudia Cavelti-Weder, Weida Li, Adrian Zumsteg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2015
Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse ModelRuben Bill, Ernesta Fagiani, Adrian Zumsteg, et al.
Pageof 2